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Background: Recently high-throughput sequencing (HTS) using next generation sequencing techniques became
useful in digital gene expression profiling.
Our study introduces analysis options for HTS data based on mapping to miRBase or counting and grouping of
identical sequence reads. Those approaches allow a hypothesis free detection of miRNA differential expression.
Methods: We compare our results to microarray and qPCR data from one set of RNA samples. We use Illumina
platforms for microarray analysis and miRNA sequencing of 20 samples from benign follicular thyroid adenoma and
malignant follicular thyroid carcinoma. Furthermore, we use three strategies for HTS data analysis to evaluate
miRNA biomarkers for malignant versus benign follicular thyroid tumors.
Results: High correlation of qPCR and HTS data was observed for the proposed analysis methods. However, qPCR is
limited in the differential detection of miRNA isoforms. Moreover, we illustrate a much broader dynamic range of
HTS compared to microarrays for small RNA studies. Finally, our data confirm hsa-miR-197-3p, hsa-miR-221-3p,
hsa-miR-222-3p and both hsa-miR-144-3p and hsa-miR-144-5p as potential follicular thyroid cancer biomarkers.
Conclusions: Compared to microarrays HTS provides a global profile of miRNA expression with higher specificity
and in more detail. Summarizing of HTS reads as isoform groups (analysis pipeline B) or according to functional
criteria (seed analysis pipeline C), which better correlates to results of qPCR are promising new options for HTS
analysis. Finally, data opens future miRNA research perspectives for HTS and indicates that qPCR might be limited in
validating HTS data in detail.
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Two decades ago miRNAs - small ribonucleic acids
about 22 nucleotides in length - have entered the scien-
tific stage and since then became recognized as import-
ant regulators of gene expression at the molecular level
[1-3]. While binding to mRNA they decide the fate of
their target by either affecting the half-life of these nu-
cleic acids or changing the translational success of the
transcript. These essential functions made their expres-
sion profiles an increasingly well studied readout in
many biological processes and diseases [4-6]. miRNAs
function in an one-to-many transcripts relationship and* Correspondence: krok@medizin.uni-leipzig.de
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reproduction in any medium, provided the orpotentially affect gene expression networks which makes
them important pathobiological markers for disease
diagnosis including cancer [7-9].
Recently high-throughput sequencing (HTS) using
next generation sequencing (NGS) techniques became
useful in digital gene expression profiling [10,11]. Short
read length and high coverage are especially suited for
counting miRNA prevalence and calculating differential
expression. Compared to qPCR, the accepted gold stand-
ard in transcript quantification, HTS offers a genome wide
approach and allows overcoming the limitations of array
based analysis which is restricted to miRNA molecules
provided by databases and suffers from cross-detection
prone hybridization methods.
So far, studies comparing the three methods are rare
and their results cannot be directly compared. Some ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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measurements [12], other show good qPCR – microarray
[13-15] or HTS – microarray [16-19] concordance.
Apart from other studies our work for the first time
compares all three methods in one set of RNA samples
from follicular thyroid tumors. In the molecular diagno-
sis of these tumors it is most important to find reliable
markers that allow an accurate classification of histologi-
cally [20] and, more important cytologically [21] incon-
clusive samples. Although both HTS and microarray
data are likely to define differentially expressed miRNAs
as potential biomarker candidates it is essential that their
differential expression is reproducible with qPCR which
is the preferable method for routine molecular diagnosis.
In our study we use Illumina platforms for microarray
analysis and miRNA sequencing of samples from benign
follicular adenoma (FA) and malignant follicular thyroid
carcinoma (FTC). Our sequencing analysis applies current
algorithms for polishing, parsing and aligning short reads
to the human genome (hg19) followed by intersecting miR
coordinates [22-26] and an adaption to the sequences
spotted on the microarrays followed by classical statis-
tical analysis of data. Moreover, we introduce an analysis
option that is not based on mapping and allows hypoth-
esis free and de novo detection of differentially expressed
miRNA isoforms. We also correlate the output of HTS
data analysis pipelines to microarray and qPCR results.
Finally, miRNAs differentially expressed between the two
types of tumor were compared to miRNA markers pro-
posed in papers which previously described FTC – FA
differences [27-29].
Methods
Thyroid tumor samples
10 follicular thyroid carcinoma (FTC) and 10 follicular
thyroid adenoma (FA) samples were selected for miRNA
profiling by HTS. Hematoxylin and eosin (HE) stained
histology sections of all tumor samples were independ-
ently rated by two experienced pathologists to guarantee
the precise tumor classification. Approval of the ethics
commission of the medical faculty of the University of
Leipzig and written consent of the respective patients
was obtained.
RNA isolation and library preparation
Total RNA was extracted from 20-50 mg snap-frozen
thyroid tissue using 1 mL Trizol reagent. Reverse tran-
scription was done with miScript Reverse Transcription
kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocols in a 10 μL reaction using 1 μg of
total RNA. 500 ng of total RNA prepared from the
tumor samples was used in the small RNA protocol with
the TruSeq™ Small RNA sample prepkit v2 (Illumina) ac-
cording to the instructions of the manufacturer. Thebarcoded libraries were size restricted between 140 and
165 bp, purified and quantified using the Library Quan-
tification Kit - Illumina/Universal (KAPA Biosystems)
according to the instructions of the manufacturer.
High-throughput sequencing
A pool of ten libraries was used for cluster generation
at a concentration of 10 nM using an Illumina cBot.
Sequencing of 50 bp was performed with an Illumina
HighScan-SQ sequencer using version 3 chemistry and
flowcell according to the instructions of the manufacturer.
High-throughput sequencing data analysis
For naming of the sequences the following nomenclature
in concordance with miRBase 18 was used. According to
miRBase the entry sequence represents the most frequent
isoform of a miRNA. A hairpin miRNA or pre-miRNA
sequence is the precursor of up to 2 canonical mature
miRNA sequences (denoted as 5p or 3p). Isoforms of
such a miRNA sequence vary around the miRBase entry
with a certain offset at the 5′ end or 3′ end or a slight
difference in nucleotide sequence (miRNA point muta-
tions and SNPs).
High-throughput sequencing data was analyzed ac-
cording to the three pipelines presented in Figure 1. The
aim of the different analysis pipelines is to measure the
expression of miRNA with different approaches: the
classical approach - alignment of reads, and two new
approaches - counting of isoforms which is independent
of any database entries and seed analysis which focuses
analysis to the bases that are most likely functionally
relevant.
At first, we removed adapters sequences from raw
reads (50 bases, fastq files) of all 20 samples (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39112)
using Cutadapt software [30]. From the remaining se-
quences only those 15–27 bases long were kept for fur-
ther analysis because they most likely contain mature
miRNA sequences. Sequences with median quality lower
than phred = 30 were discarded from the analysis. To
monitor the success of the adapter cutting and filtering
we used the FastQC program (Bioinformatics Group at
the Babraham Institute, UK).
At this point further analysis was split into pathways:
(i) mapping based pipeline A intersecting known miRNAs
coordinates from miRBase after alignment to the human
genome and (ii) pipeline B and C which count identi-
cal reads first and then annotate individual reads as
miRNA isoform when they contain a miRBase entry
sequence or map to hairpin miRNA sequences. More-
over sequences that did not succeed in this annotation
step were annotated as uncharacterized small RNA se-
quences if they align to the human genome. Pipelines
B and C aim for de novo analysis of thyroid tumor
Figure 1 Data analysis pipelines of high-throughput sequencing. Three different analysis approaches were applied to small RNA profiling in
samples from follicular thyroid tumors. Results were obtained from mapping reads to the human genome (hg19) – closest family member sequencing
(Pipeline A), mapping independent isoform sequencing (Pipeline B) and seed analysis (Pipeline C). The closest family member sequencing workflow
(Pipeline A) uses bowtie2 mapping to the human genome obtained from the public repository. The isoform sequencing pipeline returns the frequency
of each individual sequence isoform. Seed analysis merges counts of individual isoforms with the same miRNA seed sequence and therefore targets
biological importance of miRNA isoform families (sequences) which could potentially act in concert as regulators of thyroid cells.
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all sequences independent of a homology to known
miRNA molecules.The first pipeline is based on bowtie2 alignment to the
sequence of the human genome (hg19) allowing one
mismatch and alignments to multiple reference targets.
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pressed with Samtools view [31] to bam format followed
by intersecting human genomic miRNA coordinates
from miRbase (hsa.gff3) using BEDTools [26]. Reads
were counted using the R/Bioconductor programming
environment [32] by application of the ShortRead library
[33]. All counts were normalized by Reads Per Million
[34], described by the formula:
RPM ¼ RmiR=Rall  106 ð1Þ
where:
RmiR – number of reads mapped to a particular miRNA
reference in the sample,
Rall – total number of reads mapped in the sample,
RPM – normalized miRNA abundance value.
Out of the available normalization methods including
DESeq [35] and TMM [36] we have chosen RPM which
is a simple method that has been frequently used in
current miRNA studies [37,38]. Moreover, we normal-
ized our data with DESeq and compared these results to
RPM normalization (Additional file 1).
6 miRNA sequences representing low, medium and
high abundance in HTS data analysis pipeline A were
used for correlation with microarray, qPCR and HTS
data from analysis pipelines B and C (Tables 1 and 2,
Figure 2). Low and high abundance miRNAs were se-
lected from the lower and upper quartile of expression,
respectively. Medium abundance miRNAs stem from
the interquartile range. Differences between abundance
levels are significant as presented in the Table 1 and
Figure 2A.
Pipelines B and C of HTS data analysis also start
with trimmed raw sequences but count the number
of reads of each small RNA isoform present in the
fastq files. Their main goal is to identify isoform specific
and miRNA-seed specific (functional) abundance. ThisTable 1 Canonical mature miRNAs selected for qPCR
validation
miRNA
HTS (A)
qPCR target sequenceAbundance
class
RPM
hsa-miR-27b-5p Low1 (L1) 33 agagcuuagcugauuggugaac
hsa-miR-708-3p Low2 (L2) 26 caacuagacugugagcuucuag
hsa-miR-30e-5p Medium1 (M1) 3639 uguaaacauccuugacuggaag
hsa-miR-146a-5p Medium2 (M2) 1002 ugagaacugaauuccauggguu
hsa-miR-181a-5p High1 (H1) 28011 aacauucaacgcugucggugagu
hsa-miR-143-3p High2 (H2) 36537 ugagaugaagcacuguagcuccounting approach allows inclusion of sequences that do
not exactly match miRBase entry sequences or have an
offset at the 5′ or 3′ end which could be cell type or
organ specific. Moreover uncharacterized small RNAs
could be detected and evaluated. For the purpose of
counting a memory efficient Perl script was implemented
(Sequence_counter.pl). The counting algorithm is similar
to approaches proposed in the literature [35,39], however
our Perl script is designated for string operations which
is more time efficient in some cases. We further analyzed
our data with miRDeep2 [39] to find novel miRNAs in
our data set. Because this analysis did not lead to the
detection of novel miRNA species we concentrated on
the evaluation of miRNA isoforms obtained from our
counting algorithm (pipelines B and C). Counting in-
troduces a huge amount of read variants that might
contain sequencing errors or represent sequences of
unknown origin, function and small RNA classification.
Therefore, we propose a median abundance filter to re-
move RNA artifacts from the thyroid tissue data. Only
sequences detected in at least half of the 20 samples will
pass this filter and were considered in downstream ana-
lysis. Counts of sequences were also normalized to RPM
values assuming:
RmiR – number of sequence counts in the sample,
Rall – total number of reads in the sample.
Pipeline B stops at this point resulting in RPM values
obtained for each detected isoform. Normalized data
were used for the correlation analysis of 6 miRNAs and
the comparison to published FTC-FA markers.
Pipeline C continues to focus on the seed region,
known as the most important regulatory part of mature
miRNA [4,40,41]. We decided to summarize all miRNA
isoforms that share 8 base pairs at the 5′ end of the se-
quence. Moreover, in most qPCR strategies these 8 base
pairs are included in the smallest consensus target. The
task of isoform summarization was performed using the
Seed_analysis.r script in the R environment. Table 3 com-
pares the performances in the validation of miRNA
markers proposed in the literature for all three pipelines
and the DESeq algorithm [35].
Microarray data analysis
miRNA data were obtained from the Illumina scanner in
the form of normalized log2 signal intensities. Probe
sequences were re-annotated with information from
miRBase version 18 according to http://www.ebi.ac.
uk/arrayexpress/files/A-GEOD-8179/A-GEOD-8179.adf.txt.
1145 normalized microarray intensities were used for cor-
relation analysis and to compare dynamic ranges. Micro-
array data were obtained for 20 samples analyzed with
HTS, without technical replicates.
Table 2 Correlation of mean miRNA expression
qPCR (cDNA) ***0.99 *0.90 *0.86 *0.68 **0.96
- qPCR (library) *0.87 *0.90 *0.73 ***0.99
- - Array-signal *0.87 *0.82 *0.89
- - - HTS (A) **0.93 **0.95
- - - - HTS (B) *0.82
- - - - - HTS (C)
*p < 0.05,
**p < 0.01,
***p < 0.001.
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qPCR validation of miRNAs with low, medium and high
prevalence in all HTS data samples
The qPCR validation of hsa-miR-27b (L1), hsa-miR-708
(L2), hsa-miR-30e (M1), hsa-miR-146a (M2), hsa-miR-
181a (H1), and hsa-miR-143-1 (H2) was done in both,
cDNA samples prepared from the original RNAs using the
miScript RT kit (Qiagen, Hilden, Germany) according toFigure 2 qPCR validation of miRNA profiling using HTS and microarra
results of three different HTS analysis pipelines (A-C) shows a very similar e
normalized miRNA expression in 20 samples. The seed sequence for pipelin
miRNA. Best concordance of miRNA abundance is seen between microarra
(F) and HTS data analysis pipeline C (C). miRNAs were labeled according to th
M2 – hsa-miR-146a-5p, H1 – hsa-miR-181a-5p, H2 – hsa-miR-143-3p.the manufacturer’s instructions, and the library DNAs pre-
pared for HTS as described above (see library preparation).
qPCR was done in a 10 μL reaction using the miScript
SYBR Green PCR kit (Qiagen, Hilden, Germany) and
commercially available miScript Primer Assays (forward
primers; Qiagen, Hilden, Germany) and the reference
RNU6B in combination with the miScript Universal pri-
mer (reverse primer) for the cDNA templates [42], and iny data. Profiling of 6 miRNAs using microarray analysis, qPCR and
xpression pattern. Box plots present distribution of appropriately
e C is derived from the miRBase entry sequence of the respective
y data (D), qPCR from cDNA (E), qPCR from sequencing library DNA
e key: L1 – hsa-miR-27b-5p, L2 - hsa-miR-708-3p, M1 – hsa-miR-30e-5p,
Table 3 Cross-comparison of array and high-throughput sequencing data with differential regulated miRNAs from
other studies
miRNA
Regulation of FTC versus FA (fold change)
Citation Methodology Samples
HTS (A) HTS (B) HTS (C) DESeq Reference
hsa-miR-192-5p Down (0.67) Down (0.52) Down (0.50) Down (0.55) Up (1.34)
Weber et al.,
JCEM [28]
Selection of markers:
miRNA microarray
Selection 12 FTC
& 8 FA
hsa-miR-192-3p **- **- **- **-
hsa-miR-197-5p **- **- **- **- Up (1.82)
hsa-miR-197-3p Up (1.26) Up (1.50) Up (1.30) Up (1.39) Validation: qPCR Validation 5 FTC
& 4 FA
hsa-miR-328 Down (0.67) Down (0.59) Down (0.59) Down (0.62) Up (1.49)
hsa-miR-346 **- **- **- **- Up (1.39)
hsa-miR-146b-5p Up (2.26) - (1.04) - (1.06) - (0.80)
Up (2.8)
Nikiforova et al.,
JCEM [27]
Selection of markers:
qPCR assay (TaqMan
human panel with
158 miRNAs)
Selection 9 FTC
& 8 FA
hsa-miR-146b-3p Up (3.14) **- Up (1.50) **-
hsa-miR-155-5p* - (1.13) Down (0.56) Down (0.50) Down (0.58)
Up (5.5)
hsa-miR-155-3p **- **- **- **-
hsa-miR-187-5p **- **- **- **-
Up (33.4)
hsa-miR-187-3p **- **- **- **-
hsa-miR-221-5p - (0.99) **- - (0.84) **-
Up (3.6)
Validation: qPCR Validation 5 FTC
& 4 FA
hsa-miR-221-3p Up (2.01) Up (3.08) ***Up (1.78) Up (3.77)
hsa-miR-222-5p **- **- **- **-
Up (4.5)
hsa-miR-222-3p Up (1.96) Up (1.52) ***Up (1.78) Up (1.77)
hsa-miR-224-5p Up (2.26) **- **- **-
Up (6.2)
hsa-miR-224-3p **- **- **- **-
hsa-miR-199b-5p* Up (1.58) Up (1.31) - (1.04) Up (1.33) Down (0.026)
Rossing et al.,
J MolEndocrinol.
[29]
Selection of markers:
miRNA microarray Selection and
validation 12 FTC
& 12 FA
hsa-miR-199b-3p* Up (1.35) Up (1.90) - (1.19) - (1.20) Down (0.082)
hsa-miR-144-5p Down (0.53) Down (0.31) Down (0.34) Down (0.36)
Down (0.14)
Validation: leave one
out cross-validation,
cell lineshsa-miR-144-3p Down (0.47) Down (0.50) Down (0.51) Down (0.43)
*Very high miRNA abundance of one sample causes increase of mean expression in one of the two tumor groups and may affect fold change result.
**Low abundance (median RPM < 10) or no signal detected.
***miRNAs have the same seed sequence.
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library DNA templates (see Additional file 2 for qPCR
outline and primers). qPCR was performed on a Roche
LightCycler 480 according to the kit manufacturer’s
instructions. PCRs were processed through an initial de-
naturation at 95°C for 15 min and by 40 cycles of a 3-
step PCR, including 15 sec of denaturation at 94°C, a
30 sec annealing phase at 55°C and an elongation phase
at 70°C for 30 sec.
qPCR validation of hsa-miR-30 isoforms in HTS libraries
The qPCR validation of isoforms of the hsa-miR-30 fam-
ily was done in the library DNAs prepared for HTS,
which were generated as described above. qPCR was
done in a 10 μL reaction using the miScript SYBR Green
PCR kit (Qiagen, Hilden, Germany) and isoform specific
forward and reverse primers (see Additional file 2 for
qPCR outline and primers). qPCR was performed on a
Roche LightCycler 480 according to the kit manufacturer’s
instructions. PCRs were processed as detailed above.Results
High-throughput sequencing data
We analyzed 4.7 ± 1.5 million raw sequence reads per
sample (count and RPM numbers are given as mean or
mean ± standard deviation) from an Illumina small RNA
sequencing run using three pipelines (Figure 1). After
adapter cutting 6.6*10^5 ± 4.5*10^5 reads were ac-
cepted for further analysis. Direct mapping (closest
family member sequencing pipeline A) of trimmed reads
to human genomic sequences using bowtie2 resulted
in 9.9*10^5 ± 8.3*10^5 hits. These hits intersect with
1101 ± 153 out of 4446 genomic coordinates for miRbase
entries as determined by annotation using BEDtools. Our
results correspond to 91.51 ± 3.36% of all reads per sam-
ple aligned to the human genome (hg19) compared to
61.09 ± 14.45% aligned to mature miRBase sequences.
Additionally, 69.23 ± 15.79% of all reads per sample
mapped to hairpin miRBase sequences. The percentage
of reads that comprise uncharacterized small RNA se-
quences is 22.3 ± 3.2%. Additional file 3 lists the ten most
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omic origin.
In isoform analysis (pipeline B) we counted individual
sequence isoforms and normalized these counts to se-
quence abundance as reads per million (RPM). We also
compared RPM to DESeq normalization (Additional
file 1). Pearson correlation of data normalized with the
two algorithm is 0.97. One of the 20 samples had a higher
number of total reads compared to all other which re-
sulted in a separate line in the graph (see upper diagonal
line in Additional file 1). Pipeline B resulted in 18855
small, various RNA sequences that were detected in at
least half of the 20 thyroid samples. Furthermore, these
small sequences aligned to 502 ± 88 hairpin precursor
miRBase sequences. Using miRDeep2 [39] none of the
remaining uncharacterized small RNAs were identified as
new miRNAs. miRBase v18 annotation was attributed to
those isoform groups that contain an exact miRNA entry
sequence. Seed analysis (pipeline C) merged the 18855 iso-
forms from pipeline B into 5189 isoform groups with iden-
tical seed sequences (i.e. the first 8 bases of each miRNA).
Comparison of high-throughput sequencing and
microarray
First we compare average fluorescent intensities de-
tected in microarray analysis with the number of reads
mapped to all probe sequences of the miRNA expression
BeadChip v2 (Illumina) as reference. This analysis follows
the closest family member sequencing pipeline but uses
microarray probe sequences and their annotation instead
of human genome sequences. In Figure 3 we show the
comparison for all 20 thyroid samples and 1145 individual
sequences. We detect a strong saturation of microarray sig-
nal intensities compared to a wide dynamic range of the
HTS data. Moreover, miRNA sequences that were not
present in the HTS data show a wide spectrum of signal
intensities on the array (see the most left column of dots in
Figure 3). We also compared microarray signal intensities
to the results of HTS pipeline B and C (Additional file 4).
The saturation effect of the microarray is also seen in the
plot for the pipeline B data (Additional file 4A). However,
comparing microarray signal intensities to pipelines B and
C data (Additional file 4) does not reveal a meaningful
correlation.
Validation with qPCR
Table 1 shows the 6 mature miRNAs we selected for
qPCR validation based on the level of prevalence calcu-
lated with the closest family member sequencing pipe-
line A. This method outputs RPM normalized read
numbers after alignment to human genome sequences
with bowtie2 mapping software. Our selection includes
miRNAs with low, medium and high prevalence in all
HTS data samples and therefore covers a wide dynamicrange. miRNAs were selected from groups of prevalence
at random, assuming they must be abundant in all the
samples. Selected miRNAs were investigated with 2 add-
itional high-throughput sequencing analysis approaches
(pipelines B and C) using the set of 20 samples. Figure 2
summarizes analysis of HTS with pipelines A-C (2A-C),
microarray (2D) and qPCR (2E and F). As seen in the
direct comparison of microarray and HTS data, the dy-
namic range of RPM is wider than the array signal inten-
sities. This is most prominent for the medium and high
prevalence sequences (Figure 2, M1-H2). A comparison
of HTS data (pipeline A, closest family member sequen-
cing, Figure 2A) with qPCR using cDNA reverse tran-
scribed from total RNA (Figure 2E) shows a very good
concordance for 5 out of 6 miRNAs.
Correlation of small RNA qPCR and high-throughput
sequencing data
To compare HTS analysis pipelines with experimental
data from microarray and qPCR data we calculated
Pearson correlation for all three miRNA expression pro-
filing techniques. To detect the miRNA levels with the
lowest experimental noise (which might appear e.g., due
to different RT efficiencies), we used qPCR not only with
the cDNAs prepared from the original RNA samples, but
also with the HTS library DNAs as targets. Table 2 gives
the correlation coefficients of the pair wise compari-
sons between methods for the expression of the se-
lected miRNAs in 20 samples (Table 1). We observed a
good correlation between the qPCR methods and micro-
array data with a slightly better coefficient for qPCR
validation starting from reverse transcribed total RNA
(r = 0.90, p < 0.05). The correlation of qPCR and HTS
data strongly depends on the analysis pipeline. For both
qPCR methods (cDNA and library DNA) seed analysis
pipeline C (r = 0.96 and 0.99) performs much better
than the closest family member pipeline A (r = 0.86 and
0.90). Overall, the highest correlation for the HTS ana-
lysis with pipeline C is detected in the comparison to
qPCR validation of library DNA (r = 0.99, p < 0.001).
qPCR validation starting from reverse transcribed total
RNA with seed analysis pipeline C data resulted in a
very similar coefficient (r = 0.96, p < 0.01). In general,
qPCR and high-throughput sequencing data are highly
correlated when the appropriate analysis method (seed
analysis pipeline C) is applied.
Limits of qPCR validation
qPCR from cDNA template resulted in unexpected high
expression values for hsa-miR-30e (Figure 2E-M1) com-
pared to HTS analysis with pipeline A (3A). Strikingly,
DNA from the sequencing libraries (Figure 2F) as tem-
plate for qPCR led to results identical to cDNA. There-
fore, the differences for hsa-miR-30e were not explained
Figure 3 Comparison of Illumina high-throughput sequencing and Illumina miRNA Bead Arrays v2 performance in thyroid tumor samples.
Each dot represents the abundance of one mature miRNA in 1 of 20 samples in HTS (x-axis) and the fluorescent intensity of the corresponding spot on
the microarray (y-axis) of all 20 samples. Expression values are based on normalized data, assuming perfect matching of microarray probe sequence
and HTS sequence reads. The figure illustrates the saturation of microarray signals compared to the number of HTS reads and a lack of specificity of
microarray probe hybridizations by the presence of fluorescent signal for miRNA targets without any HTS reads (x-axis position -∞). Because RPM
normalization of low read counts generates visual artifact (column-like data structures between 0 and 5 RPM) we excluded all miRNAs with a very low
abundance of one or two reads in individual samples. The correlation coefficient between the microarray and HTS data set is 0.67.
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logical bias of the library preparation. These differences
are better explained by the highly diverse isoform distri-
bution (Figure 4) of hsa-miR-30e-5p (30e) and sequence
similarities to hsa-miR-30a-5p (30a), 30c-5p (30c) and
30d-5p (30d).Figure 4 Isoforms of the hsa-miR-30 family. The hsa-miR-30 family com
might interfere with expression profiling. Mapping HTS reads to the human
shown as hairpin sequences in A. Open boxes mark the sequences of matu
differentiation between the family members is marked in grey. The seed seq
only high-throughput sequencing can clearly differentiate between hsa-m
expression of hsa-miR-30e isoforms – 30e-1 and 30e-2. Means of miRNA exp
interfering sequences (i.e. 30a, c and d) are listed. Although using specific forw
family, qPCR that targets specific hsa-miR-30 family members clearly lacks spe
detection of the hairpin sequence for has-miR-30e. **- Pipeline C generates aIsoform sequencing pipeline B detects a total of 466
isoforms which share the same seed sequence but contain
offsets at both the 5′ and the 3′ end and a high number of
substitutions. The seed sequence (first 8 bases) of these
isoforms matches miRBase entry sequences for different
miRNAs of the hsa-miR-30 family. In principal, 30a, 30dprises of a large number of overlapping mature miRNA sequences that
genome (pipeline A) detects 4 significantly overlapping sequences
re 5′ miRNAs that were further validated. The sequence part that allows
uence common to all members is shown in lower case. (B) Currently,
iR-30 family members, additionally providing a chance to evaluate
ression in 20 samples using HTS data and qPCR for hsa-miR-30e-5p and
ard and reverse primers for the detection of isoforms of the hsa-miR-30
cificity to detect 1 base changes in the target sequence. *- HTS pipeline A
sum of all isoforms with the same seed sequence.
Stokowy et al. BMC Research Notes 2014, 7:144 Page 9 of 12
http://www.biomedcentral.com/1756-0500/7/144and 30e are more related since the attribution of an in-
dividual isoform to either of these miRNAs could be
based on two single nucleotide mismatches (C versus U)
in the miRBase entry sequences. The distance between
30a, 30d and 30e to 30c is a little higher (4 bases). Very
likely qPCR based on the target sequence for 30e will at
least also partially amplify targets from 30a and 30d.
Concordance of qPCR results with seed analysis pipeline
C which summarizes reads from members of the hsa-
miR-30 family with the same seed sequence will there-
fore be higher.
Evaluation of published miRNA FTC-FA markers
Table 3 summarizes sequencing results for 22 canonical
mature 5p or 3p miRs listed in miRBase which originate
from 12 hairpin pre-miRNA transcripts recently pub-
lished as FTC – FA markers [27-29]. We tested their
differential expression in our sample set of 10 FTC
and 10 FA. Our HTS analysis pipelines detect 11 to
14 of the 22 miRNAs, depending on the applied ana-
lysis pipeline. When we consider a fold-change of at
least 1.25 as increase/up-regulation and 0.8 as decrease/
down-regulation our analysis allows a call in 9 to 12 of the
22 miRNAs (Table 3). Calls from the three HTS pipe-
lines are concordant for 7 miRNAs. Best concordance
of sequencing with published data is seen for the hu-
man hairpin miRNAs 144, 146, 197, 221 and 222. For
hsa-miR-144 both 5p and 3p sequences were con-
firmed as differentially expressed. This result corroborates
to DESeq - the most frequently used RNA-Seq expression
profiling algorithm [35].
In contrast to previously published markers, the 6
miRNAs evaluated in this study do not show any signifi-
cant differences between the classes of malignity as pre-
sented in the Additional file 5.
miRNA expression profiling guidelines
In a summary of the results we propose a guidance for
miRNA expression profiling techniques. For experiments
with aim of differential expression measurements we
propose the high-throughput sequencing analysis pipe-
line based on seed analysis. This method will grant a
functional importance of findings and the highest likeli-
hood of qPCR validation success. In case of clinical stud-
ies, applied to samples with small cytological differences
the best approach is to apply the isoform sequencing
analysis pipeline. Such a method will grant the most
sensitive differentiation option and most accurate use of
HTS data. It also allows de novo detection of differentially
expressed isoforms. Finally, for experiments with known,
significant biological differences between sample classes
cost of analysis per sample is an issue so microarray tech-
niques will still be an acceptable solution. It is important
to underline that among many microarray platforms onlythose with the newest annotations (miRBase > 17) should
be considered.
Discussion
Here we present data for miRNA expression profiling
using high-throughput sequencing. Our study introduces
analysis options for HTS data based on mapping to miR-
Base or counting and grouping of identical sequence
reads without mapping. In general, direct mapping
(pipeline A) results in a miRNA expression profile that
allows referencing to existing knowledge including the
genomic origin of the miRNA. Pipeline B generates a
hypothesis free expression profile that might be most
useful in the differential diagnosis of disease. And finally,
pipeline C implements a potential functional target of
miRNAs by focusing to the seed sequence. Furthermore,
we compare HTS results to microarray data and quanti-
tative PCR from the same sample set of 20 thyroid tu-
mors. Our first analytic strategy (pipeline A) follows the
established algorithms and is focused on mapping to the
human genome. The two other strategies start with
grouping of identical sequence reads after trimming
based on full length sequence or just 8 bases known as
miRNA seed sequence. Differential expression is then
calculated for each sequence group. Groups are labeled
with the homologous miRBase entry or miRNA family.
Finally, we test the usefulness of three different pipelines
for the evaluation of follicular thyroid tumor markers and
compare the results with microarray and qPCR data.
Comparison of HTS and microarray data clearly illus-
trates the disadvantages of microarray analysis: the lack
of probe specificity and significant saturation of signal.
Direct comparison reveals that some miRNA microarray
probes that result in a fluorescent signal on the array
were not found in the HTS reads from the same sam-
ples. Among the ten probe sequences with the highest
signal intensity but without HTS reads (Additional file 6)
we detect a number of long G/C stretches that might
cause cross hybridization. Moreover, many sequences
poorly represented in HTS data show an array signal both
in raw and in normalized microarray data. This is most
likely also explained by frequent cross hybridization dur-
ing array processing, which is typical for the detection of
short targets because higher stringency washes would also
risk the loss of the specific signal.
Nevertheless, the overall correlation of microarray
analysis and HTS observed in our study is satisfactory.
Therefore, microarrays provide a global profile of miRNA
expression with relatively small experimental costs that
might lack detail and specificity but is useful for the detec-
tion of differential expression.
A close validation of 6 miRNAs leads to the conclusion
that all three investigated platforms can be cross-compared
and their data correlate to a high extent. Multiplatform
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of microarray, qPCR and HTS seed analysis (pipeline C)
patterns, which is also reflected in higher exact Pearson
correlation values. The sum of isoforms with the same seed
sequence calculated by pipeline C most likely better repre-
sents the expression of a heterogeneous family like hsa-
miR-30 although it is not able to discriminate the expres-
sion of individual family members. However, in the light of
the functional importance of the seed sequence [4,40,43]
this analysis might be of additional significance. Direct
mapping to the database sequences (pipeline A) or count-
ing only the isoform with the exact database entry se-
quence for miR-30e (pipeline B) might be the most
sequence specific analysis but very likely substantially un-
derestimates the expression and functional relevance of the
mature hsa-miR-30 family sequences. Moreover, our data
from qPCR analysis of the hsa-miR-30 family members in-
dicate that qPCR might be limited in validating HTS data
in detail. The qPCR signal with primers targeted to hsa-
miR-30e is identical to amplification of hsa-miR-30d and
only slightly lower (about 40%) than amplification of hsa-
miR-30a. In contrast, mapped reads are detected in a ratio
of 1:2:7, respectively. This suggests that most of the qPCR
signal with primers targeting hsa-miR-30e comes from
amplification of hsa-miR-30a, which implies that this qPCR
approach at least lacks specificity to detect 1 base changes
in the target sequence.
Thanks to the high accuracy of HTS reads, it is pos-
sible to evaluate miRNA abundance on the basis of indi-
vidual sequence isoforms, although it is often not easy to
unambiguously annotate a certain isoform with a miR-
Base entry. We show an example of isoform ambiguity
for the hsa-miR-30 family where the database entry se-
quence for the mature form of hsa-miR-30e differs by a
single nucleotide from hsa-miR-30a and by two nucleo-
tides from hsa-miR-30d. In addition, hsa-miR-30c is also
closely related with just 2 to 3 mismatches. Moreover,
hsa-miR-30c and hsa-miR-7, which have been reported
as papillary thyroid carcinoma biomarkers [44] cover
isoforms originating from different genome locations. In
such cases differentiation of miRNA isoforms is still diffi-
cult and requires further genome wide studies. However,
differential expression based on groups of individual se-
quence isoforms allows de novo detection of potentially
important small RNAs without previous knowledge or
changing database annotation.
miRNAs previously described in the literature as fol-
licular thyroid cancer biomarkers [27-29] do not present
isoform ambiguity, which could cause uncertainty of
HTS data evaluation. So all three HTS analysis strategies
confirmed hsa-miR-197-3p, hsa-miR-221-3p, hsa-miR-
222-3p, and both 3p and 5pof hsa-miR-144 as cancer
biomarkers in our sample set (Table 3). In contrast,
miRNAs used for technical evaluation are not differentiallyexpressed between FTC and FA, as shown in Additional
file 5.Conclusion
High-throughput sequencing added a powerful tool for
miRNA profiling. The field is rapidly moving and new
possibilities offered by HTS should be considered in any
study. Future studies need to clarify whether the ex-
pression profile of certain isoforms is of functional or
diagnostic relevance. Alternatively, it is possible that
summarizing of HTS reads by functional criteria (seed
analysis pipeline C), which better correlates to results of
qPCR and microarray is more adequate. Our data opens
perspectives for future research but still many HTS data
aspects remain to be solved.Availability and implementation
Additional files 7, 8 and 9 provide raw counts for analysis
pipelines A, B and C, respectively.
Data access for publication:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE39112.
Software implemented for the purposes of publication:
http://www.zmnieo.home.pl/autoinstalator/joomla/index.
php/bioinformatics.html.Additional files
Additional file 1: The figure shows the comparison of DESeq and
RPM normalization of Illumina high-throughput sequencing data.
Each dot represents the RPM normalized (x-axis) and DESeq normalized
(y-axis) HTS miRNA isoform data (pipeline B) for 1 of 20 thyroid cancer
HTS data samples. Pearson correlation of data normalized independently
with 2 normalizations is equal to 0.97.
Additional file 2: The table provides the qPCR outline with the
respective primers.
Additional file 3: The table lists abundant uncharacterized small
RNA sequences and gives the respective genomic origin.
Additional file 4: The figure shows the comparison of Illumina
high-throughput sequencing and Illumina miRNA Bead Arrays v2
performance in thyroid tumor samples. Each dot represents the sum
of abundance of all individual sequence isoforms generated by pipeline
B that contains the sequence of one array probe (A) or the sum of
abundance of all individual sequence isoforms generated by pipeline C
that share the same seed sequence (B) in 1 of 20 samples in HTS (x-axis)
and the fluorescent intensity of the corresponding spot (A) or
aggregation of the fluorescent intensity of corresponding spots with the
same seed sequence (B) on the microarray (y-axis) of all 20 samples.
Expression values are based on normalized data, assuming perfect
matching of microarray probe sequence and HTS sequence reads (A) or
the same seed sequence (B). The figures illustrate low correlation of
microarray signals and the number of HTS reads and a lack of specificity
of microarray probe hybridizations by the presence of fluorescent signal
for miRNA targets without any HTS reads (x-axis position -∞). The Pearson
correlation coefficient between the microarray and the HTS pipeline B or
C data sets is −0.012 and 0.040, respectively.
Additional file 5: The figure shows the expression of 6 selected
miRNAs separated by tumor malignancy condition. Consecutive rows
illustrate pipelines A, B and C, while box plot axis RPM normalized and log2
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http://www.biomedcentral.com/1756-0500/7/144transformed miRNA abundance. No significant differential miRNA expression
between tumor classes is observed in studied analysis pipelines.
Additional file 6: The table lists microarray probe sequences
without HTS reads but high fluorescent intensity.
Additional file 7: The table provides raw counts for
miR-30a-5p, −30c-5p, −30d-5p and -30e-5p as well as for
hairpin sequence of miRNA-30e (pipeline A).
Additional file 8: The spreadsheet provides raw counts for all
individual reads (pipeline B).
Additional file 9: The spreadsheet provides raw counts of all seed
family members (pipeline C).
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